Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2021
Historique:
received: 17 07 2021
accepted: 30 09 2021
entrez: 6 12 2021
pubmed: 7 12 2021
medline: 25 2 2022
Statut: epublish

Résumé

Determine predictive factors for long-term remission of acromegaly after transsphenoidal resection of growth hormone (GH)-secreting pituitary adenomas. We identified 94 patients who had undergone transsphenoidal resection of GH-secreting pituitary adenomas for treatment of acromegaly at the USC Pituitary Center from 1999-2019 to determine the predictive value of postoperative endocrine lab values. Patients underwent direct endoscopic endonasal (60%), microscopic transsphenoidal (38%), and extended endoscopic approaches (2%). The cohort was 63% female and 37% male, with average age of 48.9 years. Patients presented with acral enlargement (72, 77%), macroglossia (40, 43%), excessive sweating (39, 42%), prognathism (38, 40%) and frontal bossing (35, 37%). Seventy-five (80%) were macroadenomas and 19 (20%) were microadenomas. Cavernous sinus invasion was present in 45%. Available immunohistochemical data demonstrated GH staining in 88 (94%) and prolactin in 44 (47%). Available postoperative MRI demonstrated gross total resection in 63% of patients and subtotal resection in 37%. Most patients (66%) exhibited hormonal remission at 12 weeks postoperatively. Receiver operating characteristic (ROC) curves demonstrated postoperative day 1 (POD1) GH levels ≥1.55ng/mL predicted failure to remit from surgical resection alone (59% specificity, 75% sensitivity). A second ROC curve showed decrease in corrected insulin-like growth factor-1 (IGF-1) levels of at least 37% prognosticated biochemical control (90% sensitivity, 80% specificity). POD1 GH and short-term postoperative IGF-1 levels can be used to successfully predict immediate and long-term hormonal remission respectively. A POD1 GH cutoff can identify patients likely to require adjuvant therapy to emphasize clinical follow-up.

Identifiants

pubmed: 34867787
doi: 10.3389/fendo.2021.743052
pmc: PMC8637049
doi:

Substances chimiques

IGF1 protein, human 0
Human Growth Hormone 12629-01-5
Insulin-Like Growth Factor I 67763-96-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

743052

Informations de copyright

Copyright © 2021 Cardinal, Collet, Wedemeyer, Singer, Weiss, Zada and Carmichael.

Déclaration de conflit d'intérêts

JC: Recordati: Honoraria, advisory board Chiasma Principal investigator Crinetics Principal investigator. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Pituitary. 2014 Apr;17(2):103-8
pubmed: 23475513
J Neurooncol. 2021 Jan;151(2):313-324
pubmed: 33394265
Pituitary. 2021 Feb;24(1):53-61
pubmed: 33025547
N Engl J Med. 1990 Apr 5;322(14):966-77
pubmed: 2179724
J Endocrinol Invest. 2021 Nov;44(11):2427-2433
pubmed: 33837920
Endocrine. 2020 Apr;68(1):182-191
pubmed: 32078118
J Clin Endocrinol Metab. 2013 Aug;98(8):3190-8
pubmed: 23737543
Endocrine. 2018 Jun;60(3):415-422
pubmed: 29626274
Turk Neurosurg. 2014;24(6):906-12
pubmed: 25448208
J Clin Endocrinol Metab. 2011 Sep;96(9):2732-40
pubmed: 21715544
Clin Endocrinol (Oxf). 2013 Feb;78(2):263-70
pubmed: 22783815
J Clin Endocrinol Metab. 2005 Dec;90(12):6480-9
pubmed: 16159936
Neurosurg Focus. 2020 Jun;48(6):E10
pubmed: 32480366
Nat Rev Endocrinol. 2018 Sep;14(9):552-561
pubmed: 30050156
J Neurosurg. 2010 Apr;112(4):736-43
pubmed: 19835472
Pituitary. 2017 Feb;20(1):46-62
pubmed: 28224405
Pituitary. 2018 Jun;21(3):310-322
pubmed: 29605877
Neurol India. 2016 Mar-Apr;64(2):252-8
pubmed: 26954802
Clin Neurol Neurosurg. 2014 Nov;126:190-5
pubmed: 25278017
Neurosurgery. 2012 May;70(5):1106-13; discussion 1113
pubmed: 22067418
Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8
pubmed: 8232800
Acta Neurochir (Wien). 2014 Jul;156(7):1379-87; discussion 1387
pubmed: 24781680
J Neurosurg. 1998 Sep;89(3):353-8
pubmed: 9724106
Pituitary. 2020 Oct;23(5):582-594
pubmed: 32602066
J Endocrinol Invest. 2021 Jan;44(1):183-193
pubmed: 32441006
Eur J Endocrinol. 2008 Aug;159(2):89-95
pubmed: 18524797
J Clin Endocrinol Metab. 2010 Jul;95(7):3141-8
pubmed: 20410227
Neurosurg Focus. 2010 Oct;29(4):E6
pubmed: 20887131
J Neurosurg. 2013 Dec;119(6):1467-77
pubmed: 24074496
J Neurosurg. 2019 Oct 11;:1-11
pubmed: 31604330

Auteurs

Tyler Cardinal (T)

University of Southern California (USC) Pituitary Center, Department of Neurosurgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.

Casey Collet (C)

University of Southern California (USC) Pituitary Center, Department of Neurosurgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.

Michelle Wedemeyer (M)

University of Southern California (USC) Pituitary Center, Department of Neurosurgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.

Peter A Singer (PA)

University of Southern California (USC) Pituitary Center, Department of Neurosurgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.
Department of Medicine, Division of Endocrinology and Diabetes, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.

Martin Weiss (M)

University of Southern California (USC) Pituitary Center, Department of Neurosurgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.
Department of Medicine, Division of Endocrinology and Diabetes, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.

Gabriel Zada (G)

University of Southern California (USC) Pituitary Center, Department of Neurosurgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.

John D Carmichael (JD)

University of Southern California (USC) Pituitary Center, Department of Neurosurgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.
Department of Medicine, Division of Endocrinology and Diabetes, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH